Sun Pharmaceutical Industries Ltd. Share Price

Equities

SUNPHARMA

INE044A01036

Pharmaceuticals

Delayed NSE India S.E. 06:32:59 24/07/2024 BST 5-day change 1st Jan Change
1,611.40 INR +0.61% Intraday chart for Sun Pharmaceutical Industries Ltd. +1.10% +27.97%
Capitalization 3,843B 45.93B 3,563B P/E ratio 2025 *
35x
P/E ratio 2026 * 30x
Enterprise value 3,726B 44.53B 3,454B EV / Sales 2025 *
6.93x
EV / Sales 2026 * 6.14x
Free-Float
45.31%
Yield 2025 *
0.85%
Yield 2026 * 0.94%
More valuation ratios * Estimated data
Dynamic Chart
Sun Pharmaceutical Industries Limited Receives an Order Passed by Office of the Commissioner of Customs, (NS-III), Jawaharlal Nehru Custom House, Taluka- Uran, District-Raigad, Maharashtra CI
Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids RE
US DOJ drops Viatris unit Mylan from industry-wide antitrust probe RE
India plans incentives for diabetes, obesity drug makers in 2026, government official says RE
Sun Pharmaceutical Industries Limited Receives an Order Passed by Joint Commissioner, CGST and Central Excise, Mumbai CI
Sun Pharma Completes Taro Pharmaceutical Industries Merger MT
Sun Pharmaceutical Industries Limited acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. from Krensavage Asset Management, LLC and others for approximately CI
Sun Pharmaceutical Industries Limited Announces Results from A Phase 1, Multiple Ascending-Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Gl0034 (Utreglutide) in Obese Adults CI
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India CI
Gains in Metal, Realty Stocks Help Indian Equities End Higher MT
More news
1 day+0.63%
1 week+1.10%
Current month+5.98%
1 month+7.85%
3 months+8.48%
6 months+16.62%
Current year+27.97%
More quotes
1 week
1 555.05
Extreme 1555.05
1 615.60
1 month
1 492.30
Extreme 1492.3
1 615.60
Current year
1 257.15
Extreme 1257.15
1 638.85
1 year
1 068.35
Extreme 1068.35
1 638.85
3 years
672.55
Extreme 672.55
1 638.85
5 years
312.00
Extreme 312
1 638.85
10 years
312.00
Extreme 312
1 638.85
More quotes
Manager TitleAgeSince
Chief Executive Officer - -
Chief Executive Officer 68 31/12/81
Director of Finance/CFO - 18/06/17
Director TitleAgeSince
Chief Executive Officer 68 31/12/81
Director/Board Member 67 31/12/93
Director/Board Member 71 24/05/18
More insiders

Generic Pharmaceuticals

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+0.61%+1.10%+46.47%+129.14% 45.92B
-0.55%+1.08%+40.22%+64.18% 25.89B
-0.20%+0.67% - - 16.69B
+0.10%-0.52%+42.89%+57.68% 14.45B
+1.71%-1.54%+90.20%+92.79% 13.81B
-.--%+0.14% - - 6.79B
-1.02%+0.36%-13.69%-12.13% 6.78B
+0.38%+1.16%+23.60%+37.29% 5.73B
-.--%-1.95% - - 5.73B
+0.05%+0.56%+11.56%+22.53% 5.01B
Average +0.09%+0.64%+34.46%+55.92% 14.68B
Weighted average by Cap. +0.19%+1.12%+43.72%+84.62%
See all sector performances

Financials

Ratios2025 *2026 *
Net sales 532B 6.36B 493B 589B 7.04B 546B
Net income 110B 1.32B 102B 128B 1.53B 118B
Net Debt -157B -1.87B -145B -222B -2.65B -206B
More financial data * Estimated data
Logo Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows: - generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment; - other (6%) : primarily active pharmaceutical ingredients. At the end of March 2021, the group had 44 production plants worldwide. Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).
Employees
43,000
Calendar
Related indices
More about the company
Date Price Change Volume
24/07/24 1,611.40 +0.61% 895 507
23/07/24 1,601.60 +0.90% 1,502,677
22/07/24 1,587.35 +1.19% 826,636
19/07/24 1,568.65 -1.61% 1,649,335
18/07/24 1,594.25 +0.95% 1,665,636

Delayed Quote NSE India S.E., July 24, 2024 at 06:32 am

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
1,601.60INR
Average target price
1,629.14INR
Spread / Average Target
+1.72%
Consensus
  1. Stock Market
  2. Equities
  3. SUNPHARMA Stock